Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Panobinostat + Tazemetostat |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Panobinostat | Farydak | LBH589 | HDAC Inhibitor 45 | Farydak (panobinostat) is an HDAC inhibitor, which induces cell-cycle arrest and decreases growth of tumor cells (PMID: 18349321, PMID: 19671764, PMID: 27802904). |
| Tazemetostat | Tazverik | EPZ6438|E-7438|EPZ-6438 | EZH2 inhibitor 20 | Tazverik (tazemetostat) binds to and inhibits EZH2, resulting in decreased tri-methylation of H3K27, which potentially leads to inhibition of cell proliferation and tumor growth (PMID: 23620515). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| IDH1 R132H | high grade glioma | sensitive | Panobinostat + Tazemetostat | Preclinical - Cell culture | Actionable | In a preclinical study, cotreatment with Tazverik (tazemetostat) sensitized mouse glioma cells expressing IDH1 R132H to Farydak (panobinostat) in culture, resulting in synergistic inhibition of cell viability (PMID: 38334611). | 38334611 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|